RxDoctor Payments Data

Jessica Lehman, PA

Physician Assistant · Dover, DENPI 1467962738

Payments from drug & device makers

$1,388in general payments, 2019–2025

Across 65 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$226
  • Pfizer$187
  • Novartis$179
  • Medtronic$172
  • E.r. Squibb & Sons, L.L.C.$150
  • Abbott$136
  • plus $337 from 9 others

What the payments were for

  • Food & beverage$1,31295%
  • Education$765%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,388 in reported general payments places this provider in the 80th percentile of 527 physician assistant providers in Delaware.

See all physician assistant providers in Delaware

Medicare billing

Part B allowed, 2024
$61,581
Medicare patients
460
Services billed
1,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$82,852
XareltoRivaroxaban30$44,846
EntrestoSacubitril/Valsartan34$44,532
JardianceEmpagliflozin17$25,921
Repatha SureclickEvolocumab20$20,344
FarxigaDapagliflozin Propanediol11$15,788
Rosuvastatin Calcium136$5,330
Ezetimibe78$4,263
Atorvastatin Calcium126$2,237
Metoprolol Succinate137$2,187
Carvedilol155$1,940
Ranolazine ErRanolazine12$1,296
Losartan Potassium88$1,113
ClopidogrelClopidogrel Bisulfate60$1,034
Nifedipine ErNifedipine41$965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$187$82,85274 claims
Johnson & JohnsonXarelto$40$44,84630 claims
NovartisEntresto$179$44,53234 claims
Boehringer IngelheimJardiance$36$25,92117 claims
AstraZenecaFarxiga$226$15,78811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 527 physician assistant providers in Delaware.

Other physician assistant in Dover

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →